Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
about
Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and functionThe effect of an AGE-rich dietary extract on the activation of NF-κB depends on the cell model used.[Protein glycation as a pathological mechanism in diabetes].Dangers within: DAMP responses to damage and cell death in kidney disease.Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy.Glomerular cell death and inflammation with high-protein diet and diabetesPlasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation.Diabetes mellitus impairs tendon-bone healing after rotator cuff repair.Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: implications for age-related degenerative diseases of the eye.Review: NAD +: a modulator of immune functions.A novel improved therapy strategy for diabetic nephropathy: targeting AGEs.Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Mechanisms of distal axonal degeneration in peripheral neuropathies.Protective role of sulphoraphane against vascular complications in diabetes.Saikosaponin-d protects renal tubular epithelial cell against high glucose induced injury through modulation of SIRT3High Glucose Promotes CD36 Expression by Upregulating Peroxisome Proliferator-Activated Receptor γ Levels to Exacerbate Lipid Deposition in Renal Tubular Cells.Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro.Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury.The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells.Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis.Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats
P2860
Q28286769-332A2E52-D4A1-4DC2-AA7F-4933B88E8460Q30317876-F9AE016A-4108-4E55-BBE8-E7EC7AEC9A94Q30318169-F610FD05-175B-4F21-BC20-F4156A1D9ED0Q30380000-BBFB762F-028D-41D8-B76B-7992CFAFD1FCQ34557348-254D6B3F-095C-4EC3-9070-CE8D7576B779Q37000229-FB459542-CC14-430C-802D-054F4DB8CE46Q37176678-D189317A-4FEE-49E4-8C10-1FB72D86AAC4Q37600798-A8C0B89F-FBDE-4D82-8501-09C123FF56DEQ37626352-4548C915-E749-4ECE-A6C7-6DEFF3B73AC3Q37730290-BDB7733B-EAB5-4EBD-8D4B-4A57618DD2F3Q37986418-208CD83F-15EC-48BF-9BE5-EB3B0D0B2F92Q38077658-C1880E34-AE99-4928-ACB2-7A5877DA8899Q38200957-FFAC09BB-E04F-4121-852D-19B6DA7D598FQ38330759-5B676C51-F47B-4589-A455-21EA67D7B999Q38721709-80BFD94F-E118-4B64-86D1-E869E901F2B7Q38858222-0FF73303-4430-47F8-8E0A-D45AC8369C6EQ40215950-6B11B65A-55D1-431F-9F2D-35961E69F66DQ42115221-EB10EA40-BD2C-49F3-81D7-4D3F7640FD1AQ42182823-BAB843E9-8044-4A8B-B179-E48B6D5FEFBDQ42352562-EAFC63D7-BE2E-47C5-A6D4-E28F07005A94Q43017133-5AF63895-44D9-4F5E-8DAD-1DD9E27A7BA9Q50877793-5DF80CAD-20F9-449A-97E2-3B92932030E0Q51307150-97240AF1-31AF-4434-8ABF-D1A8A535FCE0Q57118512-9A5B198C-128D-4211-B8C8-6ECE00D80E0D
P2860
Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interactions between advanced ...... ors valid therapeutic targets.
@en
Interactions between advanced glycation end-products
@nl
type
label
Interactions between advanced ...... ors valid therapeutic targets.
@en
Interactions between advanced glycation end-products
@nl
prefLabel
Interactions between advanced ...... ors valid therapeutic targets.
@en
Interactions between advanced glycation end-products
@nl
P1433
P1476
Interactions between advanced ...... tors valid therapeutic targets
@en
P2093
Karly C Sourris
P356
10.2174/138945009787122905
P577
2009-01-01T00:00:00Z